Nosological classification (ICD-10)
Description of the dosage form
Capsules, 30 mg: size number 2, blue.
Capsules, 90 mg: size No. 2, red. On the lid of the capsule there is a white logo in the form of a ring and the letter “I” inside the ring.
Capsules contents: granules and powder of white or almost white color; the formation of conglomerates, easily crumbling with light pressure.
In preclinical and clinical studies showed the effectiveness of the drug Ingavirin ® against influenza viruses type A (A (H1N1), in
The drug Ingavirin ® contributes to the accelerated elimination of viruses, reducing the duration of the disease, reducing the risk of complications.
The mechanism of action is implemented at the level of infected cells due to the stimulation of innate immunity factors suppressed by viral proteins. In experimental studies, in particular, it has been shown that Ingavirin ® increases the expression of the interferon receptor of the first type IFNAR on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to signals of endogenous interferon. The process is accompanied by the activation (phosphorylation) of the protein STAT1 transmitter, which transmits a signal to the cell nucleus to induce antiviral genes. It is shown that under conditions of infection, the drug stimulates the production of the antiviral effector protein Moss, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication.
The drug Ingavirin ® causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced α-interferon-producing ability of blood leukocytes, stimulates the γ-interferon-producing ability of leukocytes. It causes the generation of cytotoxic lymphocytes and increases the content of NK-T-cells with high killer activity against viral-infected cells.
Anti-inflammatory effect due to the suppression of the production of key pro-inflammatory cytokines (TNF (TNF-α), IL (IL-1β and IL-6), a decrease in the activity of myeloperoxidase.
Experimental studies have shown that the joint use of the drug Ingavirin ® with antibiotics increases the effectiveness of therapy in a model of bacterial sepsis,
Experimental toxicological studies indicate a low level of toxicity and a high safety profile of the drug.
According to the parameters of acute toxicity, Ingavirin ® belongs to the 4th class of toxicity – “Low toxic substances” (when determining the LD50 in experiments on acute toxicity, it was not possible to determine the lethal doses of the drug).
The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a local irritating effect. The drug Ingavirin ® does not affect reproductive function, does not have embryotoxic and teratogenic effects.
Suction and distribution. In recommended doses, the determination of the drug in blood plasma using available techniques is not possible.
In the experiment with the use of a radioactive label it was established: the drug quickly enters the blood from the gastrointestinal tract. Evenly distributed to the internal organs. Cmax in the blood plasma and most organs is reached 30 minutes after drug administration. The AUC values for the kidneys, liver and lungs slightly exceed the blood AUC (43.77 µg · h / ml). AUC values for spleen, adrenal glands, lymph nodes and thymus are lower than blood AUC. MRT (average drug retention time) in the blood – 37.2 hours
With the course taking the drug once a day there is its accumulation in the internal organs and tissues. At the same time, the qualitative characteristics of the pharmacokinetic curves after each injection of the drug were identical: a rapid increase in the concentration of the drug after each injection 0.5–1 h after administration and then a slow decrease to 24 h.
Metabolism. The drug is not metabolized in the body and excreted unchanged.
Derivation. The main excretion process takes place within 24 hours. During this period, 80% of the administered dose is excreted: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 hours. 77 are excreted through the intestine. % of the drug and 23% through the kidneys.
Indications of drug Ingavirin ®
treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection) in adults and children from 13 years old;
prevention of influenza A and B and other acute respiratory viral infections in adults.
hypersensitivity to the active substance or any other component of the drug;
lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
children up to 13 years of age for indications “treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection)”;
Children up to 18 years of age for the indication of “prevention of influenza A and B and other acute respiratory viral infections.”
Use during pregnancy and lactation
The use of the drug during pregnancy and lactation has not been studied. If necessary, the use of the drug during lactation should stop breastfeeding.
Allergic reactions (rare).
There were no cases of interaction of the drug Ingavirin ® with other drugs.
Dosage and administration
Inside, regardless of the meal.
For the treatment of influenza and acute respiratory viral infections, adults are prescribed 90 mg 1 time per day, children 13 to 17 years old – 60 mg 1 time per day.
The duration of treatment is 5–7 days (depending on the severity of the condition). The drug is started from the moment the first symptoms of the disease appear, preferably not later than 2 days from the onset of the disease.
For the prevention of influenza and acute respiratory viral infections after contact with sick persons, adults are prescribed 90 mg 1 time a day for 7 days.
Cases of drug overdose are not described.
The drug does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in individuals of various professions, in
It is not recommended to take other antiviral drugs at the same time.
Influence on ability to steer vehicles, mechanisms. It has not been studied, but given the mechanism of action and the profile of adverse reactions, it can be assumed that the drug does not affect the ability to drive vehicles, mechanisms.
Capsules, 30 mg and 90 mg. 7 caps. in a blister strip packaging of PVC film and aluminum printed lacquered foil. 1 or 2 blister packs (for a dosage of 30 mg) or 1 blister packs (for a dosage of 90 mg) together with instructions for use are placed in a carton pack.
OAO Valenta Pharmaceutics. 141101, Moscow region, Schelkovo, ul. Factory, 2.
Tel: (495) 933-48-62; fax: (495) 933-48-63.
Claims from buyers are accepted by the manufacturing company: OAO Valenta Pharmaceutics, Russia, 141101, Moscow Region, Schelkovo, ul. Factory, 2.
Tel. (495) 933-48-62; fax (495) 933-48-63.
Pharmacy sales terms
Storage conditions of the drug Ingavirin ®
Keep out of the reach of children.
The shelf life of the drug Ingavirin ®
Do not use after the expiration date printed on the package.